EDAP Receives South Korean FDA Approval for Sonolith i-move
EDAP TMS SA (Nasdaq: EDAP) reported today the approval of its new lithotripter Sonolith i-move by South-Korean Food and Drug Administration.
South Korea is the second largest market in Asia for lithotripsy devices after Japan. This approval marks another milestone in EDAP's strategy to aggressively gain market share and reinforces the Company's 24-year presence in the South Korean market.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.